The TOUCH Prescribing Program is a restricted distribution program focused on safety and developed with the help of the Food and Drug Administration (FDA):

• Only prescribers and patients enrolled in the TOUCH Prescribing Program can prescribe and receive TYSABRI
• Only certain pharmacies and infusion sites authorized by the TOUCH Prescribing Program can dispense and infuse TYSABRI

The TOUCH Prescribing Program is designed to:

• Inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI including the increased risk of PML with treatment duration and prior immunosuppressant use.
• Warn against concurrent use with antineoplastic, immunosuppressant, or immunomodulating agents and in patients who are immunocompromised.
• Promote early diagnosis of PML and timely discontinuation of TYSABRI in the event of suspected PML.